SOURCE: BioMedReports

BioMedReports

February 22, 2010 08:08 ET

BioSante's (Nasdaq: BPAX) CEO Pleased With the Progress of LibiGel® Phase III Clinical Development Program

LOS ANGELES, CA--(Marketwire - February 22, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports today that the CEO of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), is very pleased with the new additional positive safety data from its ongoing LibiGel® Phase III clinical development program.

In an exclusive statement to BioMedReports, BioSante's Chief Exec. Officer and President, Stephen Simes stated: "This updated recommendation to continue with our Phase III clinical development safety study for LibiGel® reinforces our high hopes that we can obtain FDA approval for LibiGel.

"Furthermore, we are pleased to report that our efforts to enroll more than 2,400 women in our Cardiovascular and Breast Cancer Safety Study and approximately 500 surgically menopausal women each in our two Efficacy Trials have been proceeding as planned," Simes said.

A complete video interview with the CEO and an overview of BioSante's clinical development program is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/29458-positive-safety-data-in-phase-iii-for-biosantes-libigelr-study.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com.

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556